rss
Br J Ophthalmol 2005;89:666-669 doi:10.1136/bjo.2004.048199
  • Clinical science
    • Scientific reports

The efficacy of sirolimus in the treatment of patients with refractory uveitis

  1. V A Shanmuganathan1,
  2. E M Casely2,
  3. D Raj,
  4. R J Powell2,
  5. A Joseph1,
  6. W M Amoaku1,
  7. H S Dua1
  1. 1Department of Ophthalmology, Queens Medical Centre, Nottingham, UK
  2. 2Clinical Immunology Unit, Queens Medical Centre, Nottingham, UK
  1. Correspondence to: H S Dua Division of Ophthalmology and Visual Science, B Floor, Eye and ENT Centre, Queens Medical Centre, Nottingham NG7 2UH, UK; Harminder.Duanottingham.ac.uk
  • Accepted 16 September 2004

Abstract

Aims: To determine the efficacy of sirolimus in the treatment of patients with severe non-infectious uveitis.

Methods: Eight patients with severe non-infectious uveitis were recruited to an open study. Inclusion criteria were limited to patients whose disease was not controlled with at least two or more separate steroid sparing immunosuppressants (either because of unacceptable side effects or ineffectiveness of the drug) or who required regular doses of corticosteroids either as high dose systemic or orbital floor injections in order to control their disease. Intraocular inflammation, visual acuity, symptoms, corticosteroid burden, drug toxicity, and side effects were monitored.

Results: Sirolimus therapy was effective in five of the eight patients, all of whom had their dose of corticosteroids reduced or discontinued. Treatment in three patients was considered a failure as it caused intolerable side effects and/or failed to control the uveitis. Side effects were common and were typically gastrointestinal or cutaneous in nature. The severity of symptoms was dose dependent in most cases and occurred at trough blood levels above 25 ng/ml.

Conclusion: Sirolimus is an effective and potent immunosuppressive treatment in the majority of patients with non-infectious uveitis and can reduce the need for long term supplementary corticosteroid therapy. Further studies are required to establish the long term efficacy and safety of sirolimus alone or in combination with other steroid sparing immunosupressants.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.